CleanGo Innovations Inc. Subsidiary Kubera Black Technology to Acquire European Pharmaceutical Leader Freia Farmaceutici Srl, Targeting the Global Health Market

(TheNewswire)

VANCOUVER, BC — December 17th,2025 — TheNewswire - CleanGo InnovationsInc. (CSE: CGII; OTCQB: CLGOF; FRA: APO) (the"Company" or "CleanGo"), a publicly tradedCanadian issuer, is pleased to announce that its wholly-ownedsubsidiary, Kubera BlackTechnology Inc. ("Kubera"), onDecember 16 th , 2025 has entered into an arms length non-binding Letter ofIntent (LOI) to acquire FreiaFarmaceutici Srl ("Freia").

This Proposed Transaction is a significant strategicmove intended to expand CleanGo’s market presence into the globalhealth sector.

About Freia Farmaceutici Srl: ALeader in Plant-Based Therapeutics

Freia Farmaceutici, headquartered in Milan, Italy, wasestablished in 2009 and is recognized as a leading expert in VegetableOmegas. The company is dedicated to developing new therapeutic assetsfrom plants in an ethical and sustainable way.

Freia specializes in developing and commercializingnon-drug therapeutic solutions based on plant-derived actives,including:

• Medical Devices (bioactive substances)

• Nutritional Supplements

• Food for Special Medical Purposes

The company's approach is aligned with growingconsumer awareness regarding well-being and disease prevention,offering solutions utilizing vegetable sources with no known sideeffects.

Key Product Highlights andExpertise

Freia maintains a strong scientific focus and activelypursues clinical evidence for its portfolio.

• Plant-Based Omega Oil and ClinicalTrials: Freia is an expert in vegetable Omegas.Its ALFALIFE brand possesses significant anti-inflammatory properties,with major applications in cardiovascular diseases, obesity, and childneuropsychiatry.

• CE Marked MedicalDevices: A number of Freia's products inthe Dermolife line are registered as Class IIA Medical Devices. Theyare indicated for various dermatological conditions, including theprevention and treatment of early and late radiodermatitis, atopicdermatitis, and scar remodeling.

• Advanced AestheticMedicine: In 2016, Freia formed a partnershipwith leading international companies to acquire specific knowledge indeveloping and marketing aesthetic medicine. This expertise ischanneled into the PROMEDIAL brand, which focuses on healthy skin andaesthetic medicine purposes, offering both topical and nutraceuticalsolutions.

Pipeline

• The Freia pipeline is focused on increasing newsolutions in current therapeutic areas and developing new products inthe gynecology, gastroenterology, and pneumology fields.

• A product with applications for Multiple Sclerosis,currently registered as a food supplement, has promising clinicaltrials ongoing.

Financial Growth and StrategicVision

• Current Revenue: In 2024, Freia's gross revenue exceeded €3.1 million,with 100% of its revenue generated in the Italian market, this revenueresulted in a net positive balance sheet at the end of 2024.

• 2025 Performance: Freia is on pace to exceed its 2024 revenuenumbers.

• Expansion Strategy: Freia’s strategic expansion involves moving into otherEuropean markets. With this transaction, the company gains immediateaccess to the Canadian and US markets through the ResultingIssuer's corporate structure.

Transaction Details

Under the terms of the LOI dated December 9, 2025,Freia shareholders will exchange their outstanding securities for amaximum of twenty-five million (25,000,000) common shares in thecapital of Kubera ("Consideration Shares") the price of theshares and valuation will be explained in the Definitive Agreement tofollow shortly..

Following the Proposed Transaction, the resultingcompany (the "Resulting Issuer") will:

• Continue the business of Freia.

• Aim to complete a subsequent equity financing tosatisfy business objectives for at least twelve months.

• Establish a board of directors consisting of five (5)directors: four (4) nominated by Freia and one (1) nominated byCleanGo.

• Under the current agreement no debt long term will beassumed by Kubera.

The completion of the Proposed Transaction is subjectto, among other things, satisfactory completion of due diligence,negotiation of a definitive agreement within 45 days, and receipt ofall necessary board, shareholder, and regulatory approvals.

About CleanGo Innovations Inc.

CleanGo Innovations Inc. (CSE: CGII) is a publiclytraded Canadian company at the forefront of developing andcommercializing proprietary non-toxic and biodegradable cleaning andindustrial solutions for oil services and industrial cleaning markets.Driven by a mission for environmental sustainability, CleanGo'sinnovative product suite is designed to deliver high performance while safeguarding the planet, serving criticalcleaning needs across the oil and gas, mining, commercial, and retailsectors globally.

CleanGo Innovations Inc. believes this strategicacquisition will significantly enhance its market position byintegrating Freia’s strong pipeline of innovative, plant-basedtherapeutic solutions, particularly in the rapidly growingnutraceutical and aesthetic medicine sectors.

Contact:

Anthony Sarvucci

On behalf of the Board of Directors

President/CEO, CleanGo Innovations Inc.

For More information Contact:

Email: info@cleangogreengo.com

Phone: 346 202 6202

Forward-looking Information

This news release may contain forward-lookingstatements and forward-looking information (collectively,“forward-looking statements”) within the meaning of applicableCanadian and U.S. securities legislation. Forward-looking statementscan often be identified by words such as “will”, “plans”,“expects”, “may”, “intends”, “anticipates”,“believes”, proposes” or variations of such words includingnegative variations thereof and phrases that refer to certain actions,events or results that may, could, would, might or will occur or betaken or achieved. Actual results could differ from those projected inany forward-looking statements due to numerous factors, includingrisks and uncertainties relating to general economic, market orbusiness conditions or changes in laws, regulations and policiesaffecting the Company’s operations. Investors are cautioned thatforward-looking statements are not guarantees of future performance orevents and, accordingly are cautioned not to put undue reliance onforward-looking statements due to the inherent uncertainty of suchstatements. Any forward-looking statements included in this newsrelease are made as of the date hereof and the Company does not intendto update or revise any forward-looking statements, except asexpressly required by law.

Copyright (c) 2025 TheNewswire - All rights reserved.